INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 58 filers reported holding INFINITY PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $13 | -100.0% | 23,700 | -35.2% | 0.00% | – |
| Q3 2022 | $43,000 | +95.5% | 36,595 | +91.6% | 0.00% | – |
| Q1 2022 | $22,000 | -85.7% | 19,100 | -71.0% | 0.00% | – |
| Q4 2021 | $154,000 | -54.2% | 65,800 | -39.0% | 0.00% | – |
| Q2 2021 | $336,000 | -11.1% | 107,942 | -13.7% | 0.00% | – |
| Q1 2021 | $378,000 | +822.0% | 125,147 | +572.8% | 0.00% | – |
| Q4 2020 | $41,000 | -32.8% | 18,600 | -63.6% | 0.00% | – |
| Q4 2018 | $61,000 | +3.4% | 51,029 | +136.2% | 0.00% | – |
| Q3 2018 | $59,000 | -28.0% | 21,600 | -44.9% | 0.00% | – |
| Q2 2018 | $82,000 | 0.0% | 39,210 | 0.0% | 0.00% | – |
| Q1 2018 | $82,000 | +26.2% | 39,210 | +22.9% | 0.00% | – |
| Q4 2017 | $65,000 | +62.5% | 31,900 | +30.2% | 0.00% | – |
| Q2 2017 | $40,000 | -71.4% | 24,500 | -41.7% | 0.00% | – |
| Q1 2017 | $140,000 | +211.1% | 42,039 | +26.7% | 0.00% | – |
| Q4 2016 | $45,000 | +9.8% | 33,184 | +23.3% | 0.00% | – |
| Q3 2016 | $41,000 | +95.2% | 26,903 | +76.3% | 0.00% | – |
| Q2 2016 | $21,000 | – | 15,257 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 17,426,968 | $36,945,000 | 1.45% |
| Opaleye Management Inc. | 3,171,800 | $6,724,000 | 0.88% |
| EAM Investors, LLC | 421,103 | $893,000 | 0.15% |
| Bleichroeder LP | 250,000 | $530,000 | 0.10% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 755,593 | $1,602,000 | 0.04% |
| Callan Capital, LLC | 73,200 | $155,000 | 0.03% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 419,300 | $889,000 | 0.02% |
| Private Wealth Advisors, Inc. | 12,000 | $25,000 | 0.01% |
| Alpine Global Management, LLC | 24,575 | $52,000 | 0.01% |
| Evercore Wealth Management, LLC | 143,138 | $303,000 | 0.01% |